Compare Novo Nordisk A/S (NVO) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Victoria's Secret & Co — how do they compare? Novo Nordisk A/S trades at $45.1 (market cap $198.57B), while Victoria's Secret & Co trades at $76 (market cap $6.04B). The key difference: Novo Nordisk A/S is far larger — about 32.9× Victoria's Secret & Co's market cap, and Novo Nordisk A/S pays a 4.03% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| NVO | VSXY | |
|---|---|---|
Market Cap | $198.57B | $6.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $99.97 |
52-Week Low | $35.29 | $25.56 |
Enterprise Value | $213.37B | $8.42B |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Victoria's Secret (VSXY) trades at $78.47, up 3.85% over 24 hours, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability metrics, including a 45.27% ROE and 39.57% gross margin, but faces revenue stagnation and negative net cash flow trends. Recent news highlights PINK brand growth and Q2 2026 earnings surpassing estimates, though the stock fell due to sales concerns.
The outlook is mixed: analyst consensus is bullish with a $94.86 price target, but technical weakness and competitive pressures pose risks. Earnings momentum and cost management are key drivers for upside, while investor sentiment remains cautious amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
